专利号:US-6172235-B1 优先权日:1996-08-09 标题 :Asymmetric conjugate addition reaction 发明人:DOLLING ULF H; FREY LISA F; TILLYER RICHARD D; TSCHAEN DAVID M 权利人:MERCK & CO INC 摘要:This invention relates to a key intermediate in the synthesis of an endothelin antagonist and the synthesis of this key intermediate using an asymmetric conjugate addition reaction.
专利号:US-2015038591-A1 优先权日:2002-05-31 标 题:Compounds, compositions and methods for the treatment of tauopathies 发明人:SNOW ALAN D; CAM JUDY A; CASTILLO GERARDO; HU QUBAI; LAKE THOMAS 权利人:PROTEOTECH INC 摘要:Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of tauopathies, such as Alzheimer's disease and Parkinson's disease, and the manufacture of medicaments for such treatment.
专利号:US-7919530-B2 优先权日:2002-05-31 标 题 :Compounds, compositions, and methods for the treatment of synucleinopathies 发明人:ESPOSITO LUKE A; CUMMINGS JOEL; HUDSON F MICHAEL; SNOW ALAN D 权利人:PROTEOTECH INC 摘要:Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as Parkinson's disease, and the manufacture of medicaments for such treatment.
专利号:US-7601876-B2 优先权日:2002-05-31 标题 :Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis 发明人:SNOW ALAN D; NGUYEN BETH P; CASTILLO GERARDO M; SANDERS VIRGINIA J; LAKE THOMAS P; LARSEN LESLEY; WEAVERS REX T; LORIMER STEPHEN D; LARSEN DAVID S; COFFEN DAVID L; COFFEN CHARLOTTE 权利人:PROTEOTECH INC 摘要:Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, AA/SAA amyloidosis, such as observed in systemic AA amyloidosis and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.